High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Giving chemotherapy before a peripheral blood stem cell transplant stops the growth of cancer cells by stopping them from dividing or by killing them. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.

PURPOSE: This phase II trial is studying high-dose chemotherapy given together with peripheral blood stem cell transplant in treating patients with intestinal T-cell lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cancer Research UK
• Treatments: Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Epirubicin; Etoposide; Ifosfamide; Liposomal doxorubicin; Melphalan; Methotrexate; Prednisolone; Vincristine

Criteria

DISEASE CHARACTERISTICS:

• Newly confirmed diagnosis of intestinal T-cell lymphoma/ enteropathy-type T-cell lymphoma according to the following WHO classifications:

• Usual phenotype CD3-, CD7-positive; CD5-, CD4-, CD8-negative; or CD30-positive

• Complete surgical resection allowed

PATIENT CHARACTERISTICS:

• Unsupported neutrophils ≥ 1,500/mm^3 unless attributed to lymphomatous bone marrow infiltration

• Unsupported platelets ≥ 100,000/mm^3 unless attributed to lymphomatous bone marrow infiltration

• Creatinine clearance ≥ 50 mL/min

• Alkaline phosphatase ≤ 2.5 times upper limit of normal (ULN)

• Bilirubin ≤ 2.5 times ULN

• Left ventricular ejection fraction ≥ 50%

• Not pregnant or nursing

• Fertile patients must use effective contraception during and for ≥ 1 month after completion of study treatment

• Patients with any serious concomitant medical or psychiatric condition that would preclude them tolerating the planned treatment should be entered into the registration study only

• No known hepatitis B, hepatitis C, or HIV positivity

• No active uncontrolled cardiovascular disease

• No abnormal EKG if there is a previous history of cardiac problems

• No other severe impairment of cardiac function

• No active malignancy within the past 5 years except cervical intraepithelial neoplasia or localized skin cancer

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• Prior diagnostic or emergency surgical procedures allowed

• More than 5 years since prior treatment for malignancy

• No prior chemotherapy or radiotherapy for treatment of lymphoma